Get the Stockscreener App
19.27
0.05%
0.010
Viridian Therapeutics Inc stock is traded at $19.27, with a volume of 1.51M.
It is up +0.05% in the last 24 hours and up +11.26% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
See More
Previous Close:
$19.26
Open:
$19.39
24h Volume:
1.51M
Relative Volume:
0.61
Market Cap:
$2.13B
Revenue:
$70.92M
Net Income/Loss:
$-342.21M
P/E Ratio:
-5.119
EPS:
-3.7644
Net Cash Flow:
$-304.30M
1W Performance:
+6.88%
1M Performance:
+11.26%
6M Performance:
-41.48%
1Y Performance:
+10.18%
1-Day Range:
$19.00
$19.45
1-Week Range:
$18.14
$19.60
52-Week Range:
$13.18
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
19.27 | 2.13B | 70.92M | -342.21M | -304.30M | -3.7644 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Reiterated | Wedbush | Outperform |
| Dec-03-25 | Initiated | William Blair | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Aug-25-25 | Resumed | Jefferies | Buy |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
VRDN|Viridian Therapeutics Inc|Price:19.280|Chg%:+0.020 - TradingKey
Viridian Therapeutics stock trades around recent lows as cash runway and thyroid eye trial data shap - AD HOC NEWS
Viridian Therapeutics Inc (VRDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price-Driven Insight from (VRDN) for Rule-Based Strategy - Stock Traders Daily
Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Wells Fargo Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail
Viridian Therapeutics (VRDN) Stock Analysis: A Biotech Gem with Nearly 95% Upside Potential - DirectorsTalk Interviews
Viridian Therapeutics (VRDN) Goldman Sachs 46th Annual Global Healthcare Conference summary - Quartr
Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN) - Yahoo Finance
Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich? - Yahoo Finance
Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today - Yahoo Finance
VRDN6389238 Bond Coupon Profile — Rate & Payments - TradingView
VRDN6389238 Bond Profile — Key Metrics - TradingView
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates - MSN
Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval - Sahm
Tangible book value per share of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Total assets of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Price to book ratio of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Operating cash flow per share of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Total debt per share of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Viridian Therapeutics outlines eye disease strategy as Nasdaq-listed biotech builds its pipeline - ad-hoc-news.de
Viridian Therapeutics (VRDN) Declines Sharply as Biotech Sector Faces HeadwindsSell Signal Alerts - Bölüm Sonu Canavarı
Viridian Therapeutics to Participate in Upcoming June Investor Conferences - AOL.com
The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye Disease - Sahm
Viridian Therapeutics updates pipeline plans as thyroid eye disease program advances - AD HOC NEWS
Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone - Yahoo Finance
VRDNViridian Therapeutics Inc Options - Finviz
If You Invested $1,000 in Viridian Therapeutics Inc (VRDN) - Stock Titan
Viridian Therapeutics (VRDN) director receives 32,341 stock options at $18.48 strike - Stock Titan
Director Ajer granted 32,341 Viridian Therapeutics (VRDN) stock options at $18.48 - Stock Titan
Viridian Therapeutics (VRDN) director-linked funds receive 32,341 options - Stock Titan
Viridian Therapeutics (VRDN) director receives 32,341 options at $18.48 - Stock Titan
Fairmount-linked entities receive 32,341 Viridian (VRDN) stock options at $18.48 - Stock Titan
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval - Stocktwits
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know - The Globe and Mail
Rx Rundown: Zymeworks, Viridian Therapeutics, BioCryst and more - Medical Marketing and Media
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-07-01 - Seeking Alpha
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Jefferies Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $30 - Moomoo
VRDN Maintained by Needham -- Price Target Raised to $34.00 - GuruFocus
FDA clears Viridian's veligrotug for TED as Lumvoa - Eyes On Eyecare
Viridian's veligrotug for TED clears FDA as Lumvoa - Eyes On Eyecare
RBC Lifts Price Target on Viridian Therapeutics to $35 From $34, Keeps Outperform, Speculative Risk - Moomoo
VRDN Maintained by RBC Capital -- Price Target Raised to $35.00 - GuruFocus
Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says - marketscreener.com
VRDN Maintained by Truist Securities -- Price Target Raised to $38 - GuruFocus
VRDN Maintained by Wedbush -- Price Target Raised to $43.00 - GuruFocus
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $43 - Moomoo
Viridian Therapeutics | SCHEDULE 13G: Others - Moomoo
Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval (NASDAQ:VRDN) - Seeking Alpha
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):